BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 20440736)

  • 1. Prediction of adverse pregnancy outcomes by combinations of first and second trimester biochemistry markers used in the routine prenatal screening of Down syndrome.
    Huang T; Hoffman B; Meschino W; Kingdom J; Okun N
    Prenat Diagn; 2010 May; 30(5):471-7. PubMed ID: 20440736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First trimester predictors of adverse pregnancy outcomes.
    Brameld KJ; Dickinson JE; O'Leary P; Bower C; Goldblatt J; Hewitt B; Murch A; Stock R
    Aust N Z J Obstet Gynaecol; 2008 Dec; 48(6):529-35. PubMed ID: 19133038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-trimester or second-trimester screening, or both, for Down's syndrome.
    Malone FD; Canick JA; Ball RH; Nyberg DA; Comstock CH; Bukowski R; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Dukes K; Bianchi DW; Rudnicka AR; Hackshaw AK; Lambert-Messerlian G; Wald NJ; D'Alton ME;
    N Engl J Med; 2005 Nov; 353(19):2001-11. PubMed ID: 16282175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quad screen as a predictor of adverse pregnancy outcome.
    Dugoff L; Hobbins JC; Malone FD; Vidaver J; Sullivan L; Canick JA; Lambert-Messerlian GM; Porter TF; Luthy DA; Comstock CH; Saade G; Eddleman K; Merkatz IR; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; D'Alton ME;
    Obstet Gynecol; 2005 Aug; 106(2):260-7. PubMed ID: 16055573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-trimester repeated measures testing for Down's syndrome screening: an assessment.
    Wright D; Bradbury I; Malone F; D'Alton M; Summers A; Huang T; Ball S; Baker A; Nix B; Aitken D; Crossley J; Cuckle H; Spencer K
    Health Technol Assess; 2010 Jul; 14(33):1-80. PubMed ID: 20624355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting the result of additional second-trimester markers from a woman's first-trimester marker profile: a new concept in Down syndrome screening.
    Maymon R; Cuckle H; Jones R; Reish O; Sharony R; Herman A
    Prenat Diagn; 2005 Dec; 25(12):1102-6. PubMed ID: 16231324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Down syndrome biochemical markers and screening for preeclampsia at first and second trimester: correlation with the week of onset and the severity.
    Kang JH; Farina A; Park JH; Kim SH; Kim JY; Rizzo N; Elmakky A; Jun HS; Hahn WB; Cha DH
    Prenat Diagn; 2008 Aug; 28(8):704-9. PubMed ID: 18655226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening in early pregnancy for pre-eclampsia using Down syndrome quadruple test markers.
    Wald NJ; Morris JK; Ibison J; Wu T; George LM
    Prenat Diagn; 2006 Jun; 26(6):559-64. PubMed ID: 16700087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse pregnancy outcomes after a false-positive second trimester serum screen for Down syndrome in Thai pregnant women.
    Sritippayawan S; Vachirasrisoontra C
    J Med Assoc Thai; 2005 Apr; 88(4):449-54. PubMed ID: 16146246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of combining maternal serum alpha-fetoprotein and hCG in a second-trimester screening program for Down syndrome.
    Mooney RA; Peterson CJ; French CA; Saller DN; Arvan DA
    Obstet Gynecol; 1994 Aug; 84(2):298-303. PubMed ID: 7518896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First- and second-trimester screening: detection of aneuploidies other than Down syndrome.
    Breathnach FM; Malone FD; Lambert-Messerlian G; Cuckle HS; Porter TF; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Klugman S; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Tripp T; Bianchi DW; D'Alton ME;
    Obstet Gynecol; 2007 Sep; 110(3):651-7. PubMed ID: 17766613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repeated measurement of pregnancy-associated plasma protein-A (PAPP-A) in Down syndrome screening: a validation study.
    Palomaki GE; Wright DE; Summers AM; Neveux LM; Meier C; O'donnell A; Huang T; Knight GJ; Haddow JE
    Prenat Diagn; 2006 Aug; 26(8):730-9. PubMed ID: 16810709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-trimester marker ratios in prenatal screening for Down syndrome.
    Wald NJ; Bestwick JP; Morris JK
    Prenat Diagn; 2006 Jun; 26(6):514-23. PubMed ID: 16739232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of patient-specific risk for fetal loss using maternal characteristics and first- and second-trimester maternal serum Down syndrome markers.
    Dugoff L; Cuckle HS; Hobbins JC; Malone FD; Belfort MA; Nyberg DA; Comstock CH; Saade GR; Eddleman KA; Dar P; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; D'Alton ME;
    Am J Obstet Gynecol; 2008 Sep; 199(3):290.e1-6. PubMed ID: 18771987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-trimester biochemical screening for Down syndrome with the use of PAPP-A, AFP, and beta-hCG.
    Casals E; Fortuny A; Grudzinskas JG; Suzuki Y; Teisner B; Comas C; Sanllehy C; Ojuel J; Borrell A; Soler A; Ballesta AM
    Prenat Diagn; 1996 May; 16(5):405-10. PubMed ID: 8843997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preliminary evidence for associations between second-trimester human chorionic gonadotropin and unconjugated oestriol levels with pregnancy outcome in Down syndrome pregnancies.
    Benn PA
    Prenat Diagn; 1998 Apr; 18(4):319-24. PubMed ID: 9602476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperglycosylated-hCG (h-hCG) and Down syndrome screening in the first and second trimesters of pregnancy.
    Palomaki GE; Neveux LM; Haddow JE; Wyatt P
    Prenat Diagn; 2007 Sep; 27(9):808-13. PubMed ID: 17590886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second trimester serum markers.
    Canick JA; MacRae AR
    Semin Perinatol; 2005 Aug; 29(4):203-8. PubMed ID: 16104669
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unexplained elevated midtrimester maternal serum levels of alpha fetoprotein, human chorionic gonadotropin, or low unconjugated estriol: recurrence risk and association with adverse perinatal outcome.
    Wax JR; Lopes AM; Benn PA; Lerer T; Steinfeld JD; Ingardia CJ
    J Matern Fetal Med; 2000; 9(3):161-4. PubMed ID: 10914623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of smoking on maternal serum markers and prenatal screening in the first and second trimesters.
    Zhang J; Lambert-Messerlian G; Palomaki GE; Canick JA
    Prenat Diagn; 2011 Jun; 31(6):583-8. PubMed ID: 21480302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.